This site is intended for health professionals only

Go ahead for cancer drug trials

teaser

Article continues below this sponsored advert
Advertisement

The FDA has approved the investigational new drug application (NDA) for Enzon Pharmaceuticals’ HIF-1 alpha antagonist drug.

HIF-1 alpha is a target in many cancer types, including common solid tumours. It is a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells but high intracellular concentrations have been observed in a variety of cancers. High HIF-1 alpha concentrations are correlated with poor prognosis and resistance to therapy.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x